AustralieFrV1, PascalFrancis, Curation, bibRecord, 000960

Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia

Identifieur interne : 000960 ( PascalFrancis/Curation ); précédent : 000959; suivant : 000961

Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia

Auteurs : Frédéric Bernard [France, Australie] ; Caroline Thomas ; Jean Francois Emile ; Timothy Hercus ; Bruno Cassinat ; Christine Chomienne ; Jean Donadieu

Source :

Blood [ 0006-4971 ] ; 2002.

RBID : Pascal:02-0277138

Descripteurs français

Pascal (Inist)
- Leucémie myélomonocytaire, Chronique, Enfant, Traitement, Antagoniste, Anticancéreux, Facteur stimulant colonie granulocyte macrophage, Facteur croissance, Etude cas, Récepteur E21R.
Wicri :
- topic : Enfant.

English descriptors

KwdEn :
- Antagonist, Antineoplastic agent, Case study, Child, Chronic, Granulocyte macrophage colony stimulating factor, Growth factor, Myelomonocytic leukemia, Treatment.

Abstract

E21R is a modified granulocyte macrophage-colony-stimulating factor (GM-CSF) protein which results in antagonism of GM-CSF function via selective binding to the GM-CSF receptor complex. Juvenile chronic myelomonocytic leukemia (JMML) is a rare leukemia where spontaneous proliferation of myeloid and monocytic precursors In patients' bone marrow cultures Is dependent on GM-CSF. For patients who progress after systemic chemotherapy, there are no effective therapies. In vitro and in vivo studies in an animal model demonstrating that E21R exerts an antileukemic action prompted us to consider its potential utility in a child with end-stage JMML. E21R was well-tolerated during the 3 courses of subcutaneous treatment. A clear in vivo efficacy was observed after 2 courses of E21R but the disease appeared completely refractory during the third course. This novel therapeutic approach clearly deserves further evaluation in JMML.

A01	`01`	`1`		`@0 0006-4971`
A03		`1`		`@0 Blood`
A05				`@2 99`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia`
A11	`01`	`1`		`@1 BERNARD (Frédéric)`
A11	`02`	`1`		`@1 THOMAS (Caroline)`
A11	`03`	`1`		`@1 EMILE (Jean Francois)`
A11	`04`	`1`		`@1 HERCUS (Timothy)`
A11	`05`	`1`		`@1 CASSINAT (Bruno)`
A11	`06`	`1`		`@1 CHOMIENNE (Christine)`
A11	`07`	`1`		`@1 DONADIEU (Jean)`
A14	`01`			`@1 Pediatric Department, Hemato-Oncology Unit, CHU Montpellier @3 FRA`
A14	`02`			`@1 Pathology Department, Hôpital P Brousse @2 Villejuif @3 FRA`
A14	`03`			`@1 Pediatric Hemato-Oncology Department, CHU @2 Nantes @3 FRA`
A14	`04`			`@1 Cytokine Receptor Laboratory, Hanson Institute @2 Adelaide @3 AUS`
A14	`05`			`@1 Laboratory of Biology of Hematopoietic cells, Hôpital Saint Louis @2 Paris @3 FRA`
A14	`06`			`@1 Pediatric Hemato-Oncology Department, Hôpital Trousseau @2 Paris @3 FRA`
A20				`@1 2615-2616`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3178 @5 354000100340570480`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 6 ref.`
A47	`01`	`1`		`@0 02-0277138`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Blood`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 E21R is a modified granulocyte macrophage-colony-stimulating factor (GM-CSF) protein which results in antagonism of GM-CSF function via selective binding to the GM-CSF receptor complex. Juvenile chronic myelomonocytic leukemia (JMML) is a rare leukemia where spontaneous proliferation of myeloid and monocytic precursors In patients' bone marrow cultures Is dependent on GM-CSF. For patients who progress after systemic chemotherapy, there are no effective therapies. In vitro and in vivo studies in an animal model demonstrating that E21R exerts an antileukemic action prompted us to consider its potential utility in a child with end-stage JMML. E21R was well-tolerated during the 3 courses of subcutaneous treatment. A clear in vivo efficacy was observed after 2 courses of E21R but the disease appeared completely refractory during the third course. This novel therapeutic approach clearly deserves further evaluation in JMML.
C02	`01`	`X`		`@0 002B02R02`
C03	`01`	`X`	`FRE`	`@0 Leucémie myélomonocytaire @5 01`
C03	`01`	`X`	`ENG`	`@0 Myelomonocytic leukemia @5 01`
C03	`01`	`X`	`SPA`	`@0 Leucemia mielomonocitaria @5 01`
C03	`02`	`X`	`FRE`	`@0 Chronique @5 02`
C03	`02`	`X`	`ENG`	`@0 Chronic @5 02`
C03	`02`	`X`	`SPA`	`@0 Crónico @5 02`
C03	`03`	`X`	`FRE`	`@0 Enfant @5 03`
C03	`03`	`X`	`ENG`	`@0 Child @5 03`
C03	`03`	`X`	`SPA`	`@0 Niño @5 03`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 04`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 04`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 04`
C03	`05`	`X`	`FRE`	`@0 Antagoniste @5 05`
C03	`05`	`X`	`ENG`	`@0 Antagonist @5 05`
C03	`05`	`X`	`SPA`	`@0 Antagonista @5 05`
C03	`06`	`X`	`FRE`	`@0 Anticancéreux @5 06`
C03	`06`	`X`	`ENG`	`@0 Antineoplastic agent @5 06`
C03	`06`	`X`	`SPA`	`@0 Anticanceroso @5 06`
C03	`07`	`X`	`FRE`	`@0 Facteur stimulant colonie granulocyte macrophage @5 07`
C03	`07`	`X`	`ENG`	`@0 Granulocyte macrophage colony stimulating factor @5 07`
C03	`07`	`X`	`SPA`	`@0 Factor estimulante colonia granulocito macrófago @5 07`
C03	`08`	`X`	`FRE`	`@0 Facteur croissance @5 08`
C03	`08`	`X`	`ENG`	`@0 Growth factor @5 08`
C03	`08`	`X`	`SPA`	`@0 Factor crecimiento @5 08`
C03	`09`	`X`	`FRE`	`@0 Etude cas @5 09`
C03	`09`	`X`	`ENG`	`@0 Case study @5 09`
C03	`09`	`X`	`SPA`	`@0 Estudio caso @5 09`
C03	`10`	`X`	`FRE`	`@0 Récepteur E21R @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Hémopathie maligne @5 37`
C07	`02`	`X`	`ENG`	`@0 Malignant hemopathy @5 37`
C07	`02`	`X`	`SPA`	`@0 Hemopatía maligna @5 37`
C07	`03`	`X`	`FRE`	`@0 Myéloprolifératif syndrome @5 38`
C07	`03`	`X`	`ENG`	`@0 Myeloproliferative syndrome @5 38`
C07	`03`	`X`	`SPA`	`@0 Mieloproliferativo síndrome @5 38`
C07	`04`	`X`	`FRE`	`@0 Myélodysplasique syndrome @5 39`
C07	`04`	`X`	`ENG`	`@0 Myelodysplastic syndrome @5 39`
C07	`04`	`X`	`SPA`	`@0 Mielodisplastico síndrome @5 39`
C07	`05`	`X`	`FRE`	`@0 Cytokine @5 53`
C07	`05`	`X`	`ENG`	`@0 Cytokine @5 53`
C07	`05`	`X`	`SPA`	`@0 Citoquina @5 53`
C07	`06`	`X`	`FRE`	`@0 Polypeptide @5 54`
C07	`06`	`X`	`ENG`	`@0 Polypeptide @5 54`
C07	`06`	`X`	`SPA`	`@0 Polipéptido @5 54`
N21				`@1 161`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005779

Links to Exploration step

Pascal:02-0277138

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia</title>
<author><name sortKey="Bernard, Frederic" sort="Bernard, Frederic" uniqKey="Bernard F" first="Frédéric" last="Bernard">Frédéric Bernard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pediatric Department, Hemato-Oncology Unit, CHU Montpellier</s1>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pathology Department, Hôpital P Brousse</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Pediatric Hemato-Oncology Department, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Cytokine Receptor Laboratory, Hanson Institute</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Laboratory of Biology of Hematopoietic cells, Hôpital Saint Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Pediatric Hemato-Oncology Department, Hôpital Trousseau</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Thomas, Caroline" sort="Thomas, Caroline" uniqKey="Thomas C" first="Caroline" last="Thomas">Caroline Thomas</name>
</author>
<author><name sortKey="Emile, Jean Francois" sort="Emile, Jean Francois" uniqKey="Emile J" first="Jean Francois" last="Emile">Jean Francois Emile</name>
</author>
<author><name sortKey="Hercus, Timothy" sort="Hercus, Timothy" uniqKey="Hercus T" first="Timothy" last="Hercus">Timothy Hercus</name>
</author>
<author><name sortKey="Cassinat, Bruno" sort="Cassinat, Bruno" uniqKey="Cassinat B" first="Bruno" last="Cassinat">Bruno Cassinat</name>
</author>
<author><name sortKey="Chomienne, Christine" sort="Chomienne, Christine" uniqKey="Chomienne C" first="Christine" last="Chomienne">Christine Chomienne</name>
</author>
<author><name sortKey="Donadieu, Jean" sort="Donadieu, Jean" uniqKey="Donadieu J" first="Jean" last="Donadieu">Jean Donadieu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0277138</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0277138 INIST</idno>
<idno type="RBID">Pascal:02-0277138</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">005779</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000960</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia</title>
<author><name sortKey="Bernard, Frederic" sort="Bernard, Frederic" uniqKey="Bernard F" first="Frédéric" last="Bernard">Frédéric Bernard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pediatric Department, Hemato-Oncology Unit, CHU Montpellier</s1>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pathology Department, Hôpital P Brousse</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Pediatric Hemato-Oncology Department, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Cytokine Receptor Laboratory, Hanson Institute</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Laboratory of Biology of Hematopoietic cells, Hôpital Saint Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Pediatric Hemato-Oncology Department, Hôpital Trousseau</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Thomas, Caroline" sort="Thomas, Caroline" uniqKey="Thomas C" first="Caroline" last="Thomas">Caroline Thomas</name>
</author>
<author><name sortKey="Emile, Jean Francois" sort="Emile, Jean Francois" uniqKey="Emile J" first="Jean Francois" last="Emile">Jean Francois Emile</name>
</author>
<author><name sortKey="Hercus, Timothy" sort="Hercus, Timothy" uniqKey="Hercus T" first="Timothy" last="Hercus">Timothy Hercus</name>
</author>
<author><name sortKey="Cassinat, Bruno" sort="Cassinat, Bruno" uniqKey="Cassinat B" first="Bruno" last="Cassinat">Bruno Cassinat</name>
</author>
<author><name sortKey="Chomienne, Christine" sort="Chomienne, Christine" uniqKey="Chomienne C" first="Christine" last="Chomienne">Christine Chomienne</name>
</author>
<author><name sortKey="Donadieu, Jean" sort="Donadieu, Jean" uniqKey="Donadieu J" first="Jean" last="Donadieu">Jean Donadieu</name>
</author>
</analytic>
<series><title level="j" type="main">Blood</title>
<title level="j" type="abbreviated">Blood</title>
<idno type="ISSN">0006-4971</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Blood</title>
<title level="j" type="abbreviated">Blood</title>
<idno type="ISSN">0006-4971</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antagonist</term>
<term>Antineoplastic agent</term>
<term>Case study</term>
<term>Child</term>
<term>Chronic</term>
<term>Granulocyte macrophage colony stimulating factor</term>
<term>Growth factor</term>
<term>Myelomonocytic leukemia</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Leucémie myélomonocytaire</term>
<term>Chronique</term>
<term>Enfant</term>
<term>Traitement</term>
<term>Antagoniste</term>
<term>Anticancéreux</term>
<term>Facteur stimulant colonie granulocyte macrophage</term>
<term>Facteur croissance</term>
<term>Etude cas</term>
<term>Récepteur E21R</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">E21R is a modified granulocyte macrophage-colony-stimulating factor (GM-CSF) protein which results in antagonism of GM-CSF function via selective binding to the GM-CSF receptor complex. Juvenile chronic myelomonocytic leukemia (JMML) is a rare leukemia where spontaneous proliferation of myeloid and monocytic precursors In patients' bone marrow cultures Is dependent on GM-CSF. For patients who progress after systemic chemotherapy, there are no effective therapies. In vitro and in vivo studies in an animal model demonstrating that E21R exerts an antileukemic action prompted us to consider its potential utility in a child with end-stage JMML. E21R was well-tolerated during the 3 courses of subcutaneous treatment. A clear in vivo efficacy was observed after 2 courses of E21R but the disease appeared completely refractory during the third course. This novel therapeutic approach clearly deserves further evaluation in JMML.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-4971</s0>
</fA01>
<fA03 i2="1"><s0>Blood</s0>
</fA03>
<fA05><s2>99</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BERNARD (Frédéric)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>THOMAS (Caroline)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>EMILE (Jean Francois)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HERCUS (Timothy)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CASSINAT (Bruno)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CHOMIENNE (Christine)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DONADIEU (Jean)</s1>
</fA11>
<fA14 i1="01"><s1>Pediatric Department, Hemato-Oncology Unit, CHU Montpellier</s1>
<s3>FRA</s3>
</fA14>
<fA14 i1="02"><s1>Pathology Department, Hôpital P Brousse</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="03"><s1>Pediatric Hemato-Oncology Department, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="04"><s1>Cytokine Receptor Laboratory, Hanson Institute</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="05"><s1>Laboratory of Biology of Hematopoietic cells, Hôpital Saint Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="06"><s1>Pediatric Hemato-Oncology Department, Hôpital Trousseau</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</fA14>
<fA20><s1>2615-2616</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3178</s2>
<s5>354000100340570480</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>6 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0277138</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Blood</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>E21R is a modified granulocyte macrophage-colony-stimulating factor (GM-CSF) protein which results in antagonism of GM-CSF function via selective binding to the GM-CSF receptor complex. Juvenile chronic myelomonocytic leukemia (JMML) is a rare leukemia where spontaneous proliferation of myeloid and monocytic precursors In patients' bone marrow cultures Is dependent on GM-CSF. For patients who progress after systemic chemotherapy, there are no effective therapies. In vitro and in vivo studies in an animal model demonstrating that E21R exerts an antileukemic action prompted us to consider its potential utility in a child with end-stage JMML. E21R was well-tolerated during the 3 courses of subcutaneous treatment. A clear in vivo efficacy was observed after 2 courses of E21R but the disease appeared completely refractory during the third course. This novel therapeutic approach clearly deserves further evaluation in JMML.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Leucémie myélomonocytaire</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Myelomonocytic leukemia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Leucemia mielomonocitaria</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chronique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Chronic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Crónico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Enfant</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Child</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Niño</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Facteur stimulant colonie granulocyte macrophage</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Granulocyte macrophage colony stimulating factor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Factor estimulante colonia granulocito macrófago</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Facteur croissance</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Growth factor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Factor crecimiento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Case study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Récepteur E21R</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Myéloprolifératif syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Myeloproliferative syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Mieloproliferativo síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Myélodysplasique syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Myelodysplastic syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Mielodisplastico síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Cytokine</s0>
<s5>53</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cytokine</s0>
<s5>53</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Citoquina</s0>
<s5>53</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Polypeptide</s0>
<s5>54</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Polypeptide</s0>
<s5>54</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Polipéptido</s0>
<s5>54</s5>
</fC07>
<fN21><s1>161</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000960 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000960 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:02-0277138
   |texte=   Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia

Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri